US Court Sticks To Status Quo On Rotigotine Patch
Executive Summary
Teva’s rotigotine patches infringe a UCB patent under the doctrine of equivalents, the US Court of Appeals has confirmed in protecting UCB’s Neupro until 2021. But a polymorph patent is invalid, the court stated.